Background: Thromboprophylaxis has been determined to be safe, effective and cost-effective for hospitalised patients at venous thromboembolism (VTE) risk. However, Chinese medical institutions have not yet fully used or improperly used thromboprophylaxis. The effectiveness of information technology applied to thromboprophylaxis in hospitalised patients has been proved in many retrospective studies, lacking of prospective research evidence.
Methods: All hospitalised patients aged >18 years not discharged within 24 hours from 1 September 2020 to 31 May 2021 were prospectively enrolled. Patients were randomly assigned to the control (9890 patients) or intervention group (9895 patients). The control group implemented conventional VTE prevention programmes; the intervention group implemented an Artificial Intelligence Clinical Assistant Decision Support System (AI-CDSS) on the basis of conventional prevention. Intergroup demographics, disease status, hospital length of stay (LOS), VTE risk assessment and VTE prophylaxis were compared using the χ test, Fisher's exact test, t-test or Wilcoxon rank-sum test. Univariate and multivariate logistic regressions were used to explore the risk factor of VTE.
Results: The control and intervention groups had similar baseline characteristics. The mean age was 58.32±15.41 years, and mean LOS was 7.82±7.07 days. In total, 5027 (25.40%) and 2707 (13.67%) patients were assessed as having intermediate-to-high VTE risk and high bleeding risk, respectively. The incidence of hospital-associated VTE (HA-VTE) was 0.38%, of which 86.84% had deep vein thrombosis. Compared with the control group, the incidence of HA-VTE decreased by 46.00%, mechanical prophylaxis rate increased by 24.00% and intensity of drug use increased by 9.72% in the intervention group. However, AI-CDSS use did not increase the number of clinical diagnostic tests, prophylaxis rate or appropriate prophylaxis rate.
Conclusions: Thromboprophylaxis is inadequate in hospitalised patients with VTE risk. The role of AI-CDSS in VTE risk management is unknown and needs further in-depth study.
Trial Registration Number: ChiCTR2000035452.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582876 | PMC |
| http://dx.doi.org/10.1136/bmjoq-2023-002267 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Venous Thromboembolism Occurrence and Association with Gastrointestinal Disorders in Children with Cystic Fibrosis: An Analysis from the TriNetX Research Network Global Multicenter Real-World Dataset.
Semin Thromb Hemost
January 2025
Department of Pediatric Gastroenterology, University of South Florida Morsani College of Medicine, Tampa, Florida.
The purpose of this study is to (1) estimate and compare the prevalence of venous thromboembolism (VTE) in children (age 0 to ≤21) with versus without cystic fibrosis (CF); (2) investigate putative associations between specific gastrointestinal (GI) manifestations and the development of VTE among children with CF. This was a multicenter case-control analysis among patients aged 0 to ≤ 21 years between 2010 and 2020, using the TriNetX Research Network. Data queries included ICD-9/10 (International Classification of Diseases-9th/10th Revision) diagnosis codes.
View Article and Find Full Text PDFA review of venous thromboembolism for the hospitalist.
Postgrad Med
January 2025
Lankenau Medical Center, Wynnewood, PA, USA.
Venous thromboembolism (VTE), consisting of both deep vein thrombosis (DVT) and pulmonary embolism (PE), is an extremely common condition both in the United States and worldwide. Not only is the diagnosis associated with significant morbidity and mortality for patients, but also it imposes a deleterious financial burden on the US healthcare system. Diagnosis may be challenging due to variability in clinical presentation and requires a sequential workup including assessment of clinical pretest probability for VTE, D-dimer testing, and imaging.
View Article and Find Full Text PDFEarly Change in C-Reactive Protein and Venous Thromboembolism in Patients Treated With Immune Checkpoint Inhibitors.
JACC CardioOncol
December 2024
Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology; Comprehensive Cancer Center Vienna, Vienna, Austria.
Background: Patients with cancer treated with immune-checkpoint inhibitors (ICIs) have a substantial risk of venous thromboembolism (VTE). The association between ICI-induced inflammation and hypercoagulability is unclear, and no biomarkers currently exist to stratify VTE risk.
Objectives: The authors sought to determine the association between the early changes in C-reactive protein (CRP) after ICI initiation and the risk of VTE.
DESCRIPTION OF THE CLINICAL AND RADIOLOGICAL CHARACTERISTICS OF PULMONARY EMBOLISM IN COVID-19 VERSUS NON COVID-19 PATIENTS: A MULTICENTRIC CROSS-SECTIONAL STUDY OVER A 24-MONTH PERSPECTIVE.
J Thromb Haemost
January 2025
Medicine II Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan.
Background: COVID-19 is associated with intense systemic inflammation and abnormal coagulation profile leading to an increased incidence of pulmonary embolism (PE). This study investigates whether PE in COVID-19 patients has different clinical, laboratory and radiological characteristics when compared to traditional PE in COVID negative patients.
Methods: We conducted an observational, multicentric, cross-sectional study on consecutive patients diagnosed with PE at admission or during hospital stay from February 21 2019 to February 20 2021.
Management of post-injury anticoagulation in the traumatic brain injury patient: A scoping review.
Injury
January 2025
Washington University School of Medicine, Department of Surgery, Section of Acute and Critical Care Surgery, USA. Electronic address:
Traumatic brain injury (TBI) remains a leading cause of morbidity and mortality among trauma patients. The care of these patients continues to be a complex endeavor with prevention of associated complications, often requiring as much attention as that of the treatment of the primary injury. Paramount among these are venous thromboembolic events (VTE) due to their high incidence, additive effect on the risk of morbidity and mortality, and the careful balance that must be utilized in their diagnosis and treatment to prevent progression of the brain injury itself.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!